Evvy Raises $40 Million to Expand Vaginal Microbiome Research and Care

Women’s health company Evvy has raised a $40 million Series B, led by Catalio Capital Management, to expand its vaginal microbiome testing platform, research efforts, and work in fertility.

Founded in 2021 by Priyanka Jain, Laine Bruzek and Pita Navarro, Evvy offers an at-home vaginal microbiome test that uses metagenomic next-generation sequencing ( mNG)S. The company says its laboratory testing is CLIA-certified and CLEP-certified.

Users mail a swab sample to Evvy’s laboratory, where clinicians registered on the platform analyse and review it. Results are delivered through a patient portal alongside clinical interpretation, next steps and, when appropriate, personalised prescription care.

Evvy builds a larger dataset around women’s health

Evvy says it has served more than 100,000 patients across the United States and works with about 3,000 practitioners. Jain said the company has produced 15 peer-reviewed publications and abstracts, identified new bacterial vaginosis subtypes and documented hundreds of previously uncatalogued vaginal microbiome genomes.

The company’s broader goal is to connect microbiome biology with symptoms, treatments and health outcomes. Jain said that dataset could help clinicians improve personalised care while also supporting the discovery of new biomarkers.

She argues that precision medicine for women remains limited by a shortage of high-quality biological data representing female bodies. That gap also matters for artificial intelligence, with research examining how AI systems perform on women’s health questions.

In May, Evvy introduced EvvyAI, an assistant designed to translate the company’s microbiome data into real-time guidance for users while directing questions requiring medical expertise to clinicians.

Fertility becomes Evvy’s next major research area

Evvy is now expanding beyond vaginal health into fertility. The company is collecting data examining possible links between the vaginal microbiome and infertility, gynaecological cancer, preterm birth, IVF outcomes and recurrent pregnancy loss.

Last year, Evvy launched a prospective study using its vaginal microbiome tests in IVF clinics. Jain said the company’s long-term aim is to understand better conditions and outcomes that are still frequently described as unexplained because available medical data remains incomplete.

Evvy wants testing to cover more of women’s health

Jain said Evvy eventually hopes to develop an at-home, noninvasive test that could provide broader health insights beyond infections, including information related to inflammation, fertility, PCOS, endometriosis, perimenopause and HPV progression.

The $40 million round gives Evvy additional capital to continue building the biological dataset behind that ambition while expanding the clinical and research uses of its vaginal microbiome platform.